PHARMACEUTICAL IMPORT SETUP & ARTG APPROVAL
Become a pharmaceutical importer in Australia
HCPA helps you establish the sponsor arrangements, product approvals and compliance foundations needed to bring pharmaceutical products into the Australian market.

For businesses looking to import medicines into Australia, it is important to understand the regulatory pathway before committing to a product, overseas supplier or supply arrangement.
Still deciding whether pharmaceutical importing is the right opportunity for you?
HCPA can help you assess placement demand, commissioning, property, workforce, startup costs and the HCPA can help you assess the product, supplier, likely costs and commercial opportunity alongside the regulatory pathway before significant commitments are made.
If you decide to proceed, we can then help you move from planning into sponsor arrangements, ARTG preparation, overseas GMP requirements and market-entry readiness.
service model before significant capital is committed. If you decide to proceed, we can help you enter the sector and move through the relevant registration, accreditation or licensing pathway.
Who can become a pharmaceutical importer?
Pharmaceutical importing can suit businesses with different starting points, from established pharmaceutical companies and distributors to overseas brands and new market entrants. The right structure will depend on the product, sponsor arrangements, overseas supplier and how the business plans to enter the Australian market.
What do you need to import medicines into Australia?
There are four key parts to preparing to import pharmaceuticals into Australia: the right regulatory pathway, application and evidence requirements, overseas manufacturer and supply readiness, and the time and costs involved.

1. The right regulatory pathway
There is no single general TGA pharmaceutical import licence that applies to every pharmaceutical importing business. The approvals and authorisations depend on the product and how it will be supplied in Australia.
For most therapeutic goods, the pathway will involve:
Australian sponsor
The Australian sponsor is responsible for the product and its ARTG entry. Businesses also need access to TGA Business Services to manage applications and ARTG records.ARTG pathway
Most therapeutic goods need to be included in the Australian Register of Therapeutic Goods (ARTG) before commercial supply, unless another lawful pathway applies. Lower-risk medicines may be listed or assessed listed, while higher-risk products such as prescription medicines require more extensive assessment.Additional permits
Certain narcotic, psychotropic and precursor substances may also require an import licence or permit from the Office of Drug Control.HCPA can help identify which sponsor arrangements, registrations, approvals and permits apply and plan the right pathway from the outset.
2. Application and evidence requirements
The application needs to demonstrate that the product, sponsor and supporting evidence meet the requirements of the relevant Australian pathway.
Depending on the medicine, this may include:
- product and formulation information
- quality, safety and efficacy evidence
- sponsor and business information
- overseas manufacturer details
- GMP evidence
- product labelling and packaging information
- supporting technical documentation
- storage and distribution arrangements
- any additional permit or authorisation requirements
The level of evidence varies significantly by product. A listed medicine can follow a very different process from a prescription medicine requiring more extensive TGA evaluation.
HCPA can help coordinate the application, supporting evidence and regulatory documentation required for the relevant pathway.
3. Manufacturer and supply readiness
The overseas manufacturer and Australian supply arrangements need to support the regulatory pathway before commercial supply begins.
Relevant overseas manufacturing sites may require GMP clearance or certification. The manufacturer also needs to be able to provide the quality and product evidence required for Australia.
You should also have appropriate systems in place for:
- quality agreements
- batch or lot controls
- expiry and traceability records
- product-specific storage conditions
- warehousing and distribution
- temperature control where required
- ongoing product and supplier oversight
Assessing these arrangements early can help avoid committing to a supplier or import model that cannot support Australian requirements.
Learn about ongoing pharmaceutical import compliance requirements
4. Timeframes and costs
There is no single timeframe or cost for becoming a pharmaceutical importer because these depend heavily on the product, ARTG pathway and overseas manufacturing arrangements.
The overall investment and timeframe can be influenced by:
- TGA application and evaluation fees
- overseas GMP clearance or certification
- requests for further information
- product testing and supporting evidence
- packaging or labelling changes
- freight and customs
- storage and distribution
- insurance
- inventory and working capital
- professional and regulatory support
A listed medicine will generally have a very different cost and assessment pathway from a prescription medicine requiring more extensive TGA evaluation. Additional assessment of overseas manufacturing arrangements can also increase the time and investment required.
A clear understanding of the pathway before committing to stock or supplier agreements can reduce avoidable delays and unexpected costs.
HCPA can help you map the regulatory process, likely costs and preparation requirements upfront so you have a clearer pathway to entering the Australian market.
Why work with HCPA when starting a pharmaceutical import business?
Pharmaceutical importing is easier to navigate when the product, supplier, regulatory pathway and commercial model are considered together from the beginning.
It is never too early to speak with HCPA. Whether you are still assessing a product opportunity or ready to begin the regulatory process, we can help you understand the commercial and regulatory requirements and plan the right pathway into the Australian market.
HCPA can help you establish who will hold responsibility for the product, how it can enter the Australian market and what needs to be in place before commercial supply begins.
How HCPA helps you start importing pharmaceuticals
Confirm your import model
We review your proposed products, overseas supplier or manufacturer and Australian supply model to clarify how you plan to enter the market.
Map the regulatory pathway
We identify the sponsor arrangements, ARTG pathway, overseas GMP requirements and any additional approvals or permits that may apply.
Prepare your application
HCPA coordinates the product evidence, GMP information, quality arrangements and regulatory documentation needed to support the relevant application pathway.
Prepare for market entry
We support the application process, help respond to regulatory requests and put the required foundations in place for successful market entry.
Our experience helping businesses enter regulated markets
businesses supported
consultants
first-time approval rate
client revenue generated
HCPA has extensive experience helping businesses enter regulated markets, understand approval requirements and establish the operational foundations needed to move from opportunity to market entry.
For pharmaceutical importers, we apply that regulatory and operational experience to sponsor arrangements, ARTG pathways, overseas manufacturing requirements and market-entry planning, helping you move from an overseas product opportunity to a structured pathway into Australia.
Frequently asked questions about starting a pharmaceutical import business
What are the regulatory requirements for importing medicines into Australia?
Therapeutic goods generally need an Australian sponsor and inclusion in the ARTG before commercial import and supply, unless another lawful pathway applies.
Depending on the medicine, additional requirements may include TGA assessment, GMP clearance for overseas manufacturers or specific import permits.
Who can help me establish the sponsor arrangements, registrations and compliance systems needed to import pharmaceutical products?
A pharmaceutical regulatory consultant can help determine the sponsor structure, ARTG pathway, overseas GMP requirements and compliance foundations needed for the proposed product.
HCPA can coordinate these requirements from initial product assessment through to application and market-entry preparation.
Is there a pharma import licence in Australia?
There is no single general TGA import licence covering all pharmaceutical products.
Most therapeutic goods instead require an Australian sponsor and ARTG inclusion or another lawful authorisation. Some controlled substances may also require an Office of Drug Control import licence or permit.
Do I need an Australian sponsor to import medicines?
For commercial supply, the product generally needs an Australian sponsor responsible for its ARTG entry. The sponsor may import the product directly or arrange for another party to do so.
Does every imported medicine need to be registered on the ARTG?
Therapeutic goods generally need to be included in the ARTG before commercial supply unless another lawful pathway applies, but not every medicine is registered.
Depending on the medicine, it may be listed, assessed listed or registered.
What is the difference between a listed and registered medicine?
Listed medicines are generally lower-risk medicines where the sponsor certifies that applicable requirements are met.
Higher-risk registered medicines undergo greater TGA assessment and may require evidence of quality, safety and efficacy.
Does an overseas pharmaceutical manufacturer need a TGA manufacturing licence?
No. TGA manufacturing licences apply to Australian manufacturing sites.
For overseas manufacturers, appropriate GMP clearance or certification may apply instead.
Can the TGA inspect an overseas pharmaceutical manufacturer?
Yes. Depending on the GMP pathway and available evidence, the TGA may inspect an overseas manufacturing site.
Is pharmaceutical importing a viable business opportunity in Australia?
It can be where a business identifies a product with genuine Australian demand, a workable regulatory pathway and an overseas manufacturer capable of supporting the required quality and evidence standards.
Australia relies heavily on imported medicines, but the size of the overall market does not automatically make an individual product commercially viable. Demand, competition, regulatory complexity, supplier capability and likely margins all need to be assessed together.
HCPA can help you assess whether the product and import model provide a realistic foundation to enter the market before significant capital is committed.
What does it cost to start a pharmaceutical import business?
There is no standard startup cost because the investment depends heavily on the product and regulatory pathway.
Costs can include product sourcing, TGA applications, overseas GMP clearance, testing, packaging or labelling changes, freight, storage, distribution, insurance, inventory and working capital. More complex registered medicines can involve significantly greater regulatory and evidence costs than lower-risk listed medicines.
HCPA can help you map these costs against the proposed product and regulatory pathway before you proceed.
How should I assess an overseas pharmaceutical manufacturer?
Confirm that the manufacturer can consistently supply the product, meet the applicable quality and GMP requirements and provide the evidence needed for the Australian regulatory pathway.
This should be assessed before entering a significant supply arrangement, as an otherwise attractive product may not be viable if the manufacturer cannot support Australian requirements.
How can I assess whether an imported pharmaceutical product will be profitable?
Start with realistic Australian demand and selling prices, then assess these against the full landed and ongoing cost of supplying the product.
Consider supplier pricing, freight, regulatory and compliance costs, warehousing, distribution margins, inventory, working capital and operating costs. The opportunity needs sufficient volume and margin to justify both the upfront investment and ongoing sponsor responsibilities.
HCPA can help bring the commercial model and regulatory pathway together so you can make a better-informed decision before entering the market.
What should a pharmaceutical import business plan include?
A pharmaceutical import business plan should bring together the target product, Australian demand, overseas supplier, sponsor and ARTG pathway, regulatory costs, pricing, margins, logistics, distribution, inventory and expected timeframe to market.
It should also account for the main commercial and regulatory risks so these can be assessed before significant commitments are made.
What should I check before agreeing to import an overseas pharmaceutical product?
Before committing, assess:
- the ARTG pathway
- sponsor arrangements
- overseas GMP position
- available product evidence
- Australian labelling requirements
- storage and distribution requirements
- any additional permits
Confirming these requirements early helps determine whether the product can move into the Australian market through a workable regulatory pathway.
Can TGA requirements delay an imported medicine entering the market?
Yes. More complex applications may involve requests for further information, clarification or additional scrutiny of overseas manufacturing arrangements, which can increase the time and cost to market.
Should I sign a supply agreement before confirming the TGA pathway?
Ideally, understand the Australian regulatory pathway and manufacturer requirements before making significant commercial commitments.
A product may appear commercially attractive until the evidence, GMP and regulatory investment required to bring it to market are factored in.
What happens after the product is approved for import and supply?
The sponsor’s responsibilities continue after market entry, including maintaining applicable product approvals, overseas GMP arrangements and ongoing product compliance.
Related pharmaceutical importing resources
Managingongoing compliance
Need help keeping your import operation compliant?
Growing your import business
Ready to grow your pharmaceutical import business?
Identify new product opportunities, strengthen overseas supplier relationships and build Australian distribution partnerships that support sustainable growth across your pharmaceutical portfolio.
Start growingWhat Our Clients Say

